Skip to main content
. 2019 Apr 3;13:921. doi: 10.3332/ecancer.2019.921

Table 5. Efficacy of chemotherapy regimens. Bracketed figures are percentage values.

Regimen Best response on CT Clinical benefit rates Progression-free survival (months)
SD PR SD + 3C chemo PR + 3C chemo Mean Median Interquartile range
Total patients 31 (36) 28 (32) 26 (30) 19 (22) 9.6 8.0 2.9–12.5
Anthracyclines 9 (36) 8 (32) 8 (32) 6 (24) 8.4 8.0 2.6–11.6
Capecitabine 12 (39) 10 (32) 10 (32) 6 (19) 11.7 9.2 3.2–15.8
Taxanes 8 (38) 7 (33) 7 (33) 4 (19) 8.8 7.8 3.0–11.3
Others 2 (20) 3 (30) 1 (10) 3 (30) 5.4 4.9 2.0–9.1